Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK1 | P23458 | 18/20 | 0.60 |
| ▸ | TYK2 | P29597 | 1/20 | 0.46 |
| ▸ | KIT | P10721 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30355925 | 1.00 | JAK1 (0.60) | JAK1TYK2KIT | |
| SCHEMBL20918426 | 0.85 | JAK1 (0.81) | JAK1 | |
| SCHEMBL20918015 | 0.81 | JAK1 (0.71) | JAK1 | |
| SCHEMBL30356056 | 0.81 | JAK1 (0.71) | JAK1 | |
| SCHEMBL20918692 | 0.77 | JAK1 (0.76) | JAK1 | |
| SCHEMBL30356216 | 0.77 | JAK1 (0.74) | JAK1TYK2 | |
| SCHEMBL20918119 | 0.77 | JAK1 (0.74) | JAK1TYK2 | |
| SCHEMBL30009502 | 0.76 | KIT (0.64) | KIT | |
| SCHEMBL20917996 | 0.76 | JAK1 (0.75) | JAK1 | |
| SCHEMBL30356129 | 0.76 | JAK1 (0.75) | JAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11524968-B2 | Heterocyclic compound as a protein kinase inhibitor | HK INNO.N CORPORATION (KR) | 2022-12-13 | — | — | US | claimed |
| US-20210171544-A1 | Heterocyclic Compound as a Protein Kinase Inhibitor | HK INNO.N CORPORATION (KR) | 2021-06-10 | — | — | US | claimed |
| CN-111372931-B | Heterocyclic compounds as protein kinase inhibitors | 怡诺安有限公司 | 2023-03-24 | — | — | CN | disclosed |
| US-11524968-B2 | Heterocyclic compound as a protein kinase inhibitor | HK INNO.N CORPORATION (KR) | 2022-12-13 | — | — | US | disclosed |
| US-11524968-B2 | Heterocyclic compound as a protein kinase inhibitor | HK INNO.N CORPORATION (KR) | 2022-12-13 | — | — | US | disclosed |
| US-20210171544-A1 | Heterocyclic Compound as a Protein Kinase Inhibitor | HK INNO.N CORPORATION (KR) | 2021-06-10 | — | — | US | disclosed |
| US-20210171544-A1 | Heterocyclic Compound as a Protein Kinase Inhibitor | HK INNO.N CORPORATION (KR) | 2021-06-10 | — | — | US | disclosed |
| EP-3697787-A1 | HETEROCYCLIC COMPOUND AS A PROTEIN KINASE INHIBITOR | HK inno.N Corporation (KR) | 2020-08-26 | — | — | EP | disclosed |
| CN-111372931-A | Heterocyclic compounds as protein kinase inhibitors | 韩科创新株式会社 | 2020-07-03 | — | — | CN | disclosed |
| WO-2019078619-A1 | HETEROCYCLIC COMPOUND AS A PROTEIN KINASE INHIBITOR | CJ HEALTHCARE CORPORATION (KR) | 2019-04-25 | — | — | WO | disclosed |
| WO-2019078619-A1 | HETEROCYCLIC COMPOUND AS A PROTEIN KINASE INHIBITOR | CJ HEALTHCARE CORPORATION (KR) | 2019-04-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210171544-A1 | Heterocyclic Compound as a Protein Kinase Inhibitor | MAP3K20, MAP3K15, MAP3K1 | JAK1 83/4885TYK2 174/4885KIT 3668/4885 |
| US-11524968-B2 | Heterocyclic compound as a protein kinase inhibitor | MAP3K20, MAP3K15, MAP3K1 | JAK1 83/4885TYK2 174/4885KIT 3668/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.